Skip to main content


Fig. 2 | Virology Journal

Fig. 2

From: Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach

Fig. 2

HPV16 and HPV73 neutralizing antibody elicited by vaccination of mice with L2-recombinant adenoviruses either with or without adjuvant. Legend: Balb/c mice (5/group) were vaccinated s.c. three times at 3 week intervals with 1010 L2 or HA-recombinant adenovirus particles either in the absence (a) or presence (b) of adjuvant (50 μg aluminum hydroxide gel and 5 μg monophosphoryl lipid A), or controls Gardasil (0.1x human dose) or phosphate-buffered saline (PBS). Serum was collected 3 weeks after the final immunization and two-fold dilutions tested by for in vitro neutralization of HPV16 (A, B) or HPV73 (c) pseudovirions. Purified RG-1 monoclonal antibody was included as a positive control for L2-specific neutralization and diluted from 1 μg/μL. A neutralization titer of <1:50 is considered Not Detectable (ND) and mean titer is shown. (d) A web-based T-coffee tool was used for the CLUSTAL W (1.83) multiple sequence alignment ( comparison of the amino acid sequences of HPV16 L2 12–41 and the comparable regions of HPV56 and HPV73 color coded by amino acid side chain. The alignment is shown and identity is marked below with an asterisk and a conservative change with a colon

Back to article page